Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zeno Riester"'
Autor:
Anna Bielowski, Teresa Kilian, Sarah Rümpeler Calheiros Vera-Cruz, Zeno Riester, Sabrina Prommersberger, Julia Beckmann, Martin Kortüm, Leo Rasche, Hermann Einsele, Michael Hudecek, Sophia Danhof
Publikováno v:
HemaSphere, Vol 7, p e5328352 (2023)
Externí odkaz:
https://doaj.org/article/d8e4727760a9497291bbf1b9a961fa90
Autor:
Maik Luu, Zeno Riester, Adrian Baldrich, Nicole Reichardt, Samantha Yuille, Alessandro Busetti, Matthias Klein, Anne Wempe, Hanna Leister, Hartmann Raifer, Felix Picard, Khalid Muhammad, Kim Ohl, Rossana Romero, Florence Fischer, Christian A. Bauer, Magdalena Huber, Thomas M. Gress, Matthias Lauth, Sophia Danhof, Tobias Bopp, Thomas Nerreter, Imke E. Mulder, Ulrich Steinhoff, Michael Hudecek, Alexander Visekruna
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
The activity of immune cells can be regulated by the microbiome. Here, the authors show that the fatty acids pentanoate and butyrate—normally released by the microbiome—increase the anti-tumour activity of cytotoxic T lymphocytes and chimeric ant
Externí odkaz:
https://doaj.org/article/b049d4b46e18405fa995dd666bce268c
Autor:
Viktor Umansky, Peter Altevogt, Jochen Utikal, Vincenzo Bronte, Carsten Kirschning, Vasyl Nagibin, Qian Sun, Laura Hüser, Zeno Riester, Christopher Groth, Rebekka Weber, Céline Weller, Xiaoying Hu, Viktor Fleming
Tumor cell–derived extracellular vesicles (EV) convert normal myeloid cells into myeloid-derived suppressor cells (MDSC), inhibiting antitumor immune responses. Here, we show that EV from Ret mouse melanoma cells upregulate the expression of progra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30134e5df523fa5d595f477cc6671751
https://doi.org/10.1158/0008-5472.c.6511317.v1
https://doi.org/10.1158/0008-5472.c.6511317.v1
Autor:
Viktor Umansky, Peter Altevogt, Jochen Utikal, Vincenzo Bronte, Carsten Kirschning, Vasyl Nagibin, Qian Sun, Laura Hüser, Zeno Riester, Christopher Groth, Rebekka Weber, Céline Weller, Xiaoying Hu, Viktor Fleming
Figure S1 shows PD-L1 upregulation induced by EV that is mediated by NF-kB activation; Figure S2 shows an induction of PD-L1 and immunosuppressive capacity of myeloid cells through TLR signaling; Figure S3 presents characterization of EV derived from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cecab5e60228f0bc40f6e2d39a8b7d
https://doi.org/10.1158/0008-5472.22422705
https://doi.org/10.1158/0008-5472.22422705
Autor:
Teresa Kilian, Verena Konetzki, Anna Schmidt, Sophia Danhof, Zeno Riester, Michael Hudecek, Hermann Einsele, Kersten Heyer, Sabrina Prommersberger
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S41
Background Recent and soon-to-expect approvals have significantly increased the number of patients treated with CAR-T cells and clinical responses can be very impressive. However, side effects including cytokine storm, neurotoxicity or on-target/off-
Autor:
Christian Klein, Sebastian Kobold, Floriana Cremasco, Mohamed Benmebarek, Renier Myburgh, Pablo Umana, Kay Stubenrauch, Anne Freimoser-Grundschober, Christian Jost, Mario Perro, Uwe Wessels, Ekkehard Mössner, Diana Darowski, Zeno Riester, Jörg Benz
Publikováno v:
Cancer Research. 80:4229-4229
Introduction: In the rapidly growing field of chimeric antigen receptor (CAR) engineered T cells new approaches aim to make CAR-T cell therapy safer and more effective. Recent, designs aim towards universal or modular CARs that do not directly recogn
Autor:
Christopher Groth, Carsten Sticht, Peter Altevogt, Xiaoying Hu, Alina Siebenmorgen, Viktor Umansky, Laura Hüser, Jochen Utikal, Rebekka Weber, Zeno Riester
Publikováno v:
Journal for Immunotherapy of Cancer
BackgroundMyeloid-derived suppressor cells (MDSC) play a major role in the immunosuppressive melanoma microenvironment. They are generated under chronic inflammatory conditions characterized by the constant production of inflammatory cytokines, chemo
Publikováno v:
Current Opinion in Oncology
Purpose of review Immunotherapy with gene-engineered chimeric antigen receptor (CAR)-T cells has curative potential in advanced malignancies and undergoes a surging preclinical and clinical development. Here, we present a selection of new targets and